How many daraxonrasib clinical trials are there?

8 daraxonrasib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 7 are actively recruiting participants.

Are daraxonrasib clinical trials recruiting in 2026?

Yes — 7 daraxonrasib trials are actively recruiting in 2026, with 144 U.S. sites across 34 states. See the recruiting trials and the per-state site list further down this page.

What conditions is daraxonrasib being studied for?

daraxonrasib is being studied for PDAC, Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma, NSCLC and 21 more. The trials are grouped by indication on this page.

What phase is daraxonrasib in?

daraxonrasib clinical trials span 3 Phase 3, 1 Phase 2, 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors daraxonrasib clinical trials?

The lead sponsor across the most daraxonrasib trials is Revolution Medicines, Inc., with 1 additional lead sponsor listed in the data. Each trial row links to the full study detail page including sponsor information.

daraxonrasib Clinical Trials (2026): 8 Studies for PDAC & Pancreatic Cancer

Creator: Hipa.ai Research
Published: 2026-06-02T17:26:18.735Z

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: September 24, 2026.

8 daraxonrasib clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 7 indications (including PDAC & Pancreatic Cancer) and 3,728 total planned enrollment. 3 Phase 3 daraxonrasib trials and 1 Phase 2 are listed. 7 daraxonrasib clinical trials are actively recruiting at 144 U.S. sites across 34 states. Most recent activity: NCT07492680 (May 2032).

Where to Participate: All daraxonrasib Trial Sites in the U.S. (144 sites across 34 states)

Every actively recruiting daraxonrasibtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

State	Facility	City	Trial	Map
AL	Alabama Oncology	Birmingham35243	NCT06881784	Map
AZ	Mayo Clinic	Phoenix85054	NCT07252232	Map
AZ	Mayo Clinic - Scottsdale	Phoenix85054	NCT07491445	Map
AZ	Honor Health Research Institute	Scottsdale85258	NCT07491445	Map
AZ	HonorHealth Research Institute	Scottsdale85258	NCT07252232	Map
CA	UC San Diego Moores Cancer Center	La Jolla92037	NCT07252232	Map
CA	MemorialCare Long Beach Medical Center	Long Beach90806	NCT06881784	Map
CA	Cedars-Sinai Cancer at Cedars-Sinai Medical Center	Los Angeles90048	NCT07252232	Map
CA	University of California Los Angeles Health - Hematology/Oncology	Los Angeles90095	NCT07491445	Map
CA	University of California, Los Angeles	Los Angeles90404	NCT07252232	Map
CA	USC Norris Comprehensive Cancer Center	Los Angeles90033	NCT07397338	Map
CA	UC IRVINE Health	Orange92868	NCT06128551	Map
CA	Stanford Cancer Institute	Palo Alto94304	NCT07252232	Map
CA	UC Davis Comprehensive Cancer Center	Sacramento95817	NCT06128551	Map
CA	University of California, Davis Comprehensive Cancer Center	Sacramento95817	NCT07252232	Map
CA	University of California San Francisco	San Francisco94158	NCT07491445	Map
CA	University of California, San Francisco	San Francisco94143	NCT07252232	Map
CA	Stanford Cancer Institute	Stanford94305	NCT06128551	Map
CO	University of Colorado Cancer Center	Aurora80045	NCT06128551	Map
CO	Rocky Mountain Cancer Centers, LLP	Lakewood80228	NCT07252232	Map
CT	Hartford Healthcare	Hartford06103	NCT07252232	Map
CT	Yale Cancer Center	New Haven06511	NCT07349537	Map
CT	Yale University, Smillow Cancer Center	New Haven06519	NCT06881784	Map
CT	Eastern Connecticut Hematology and Oncology Associates	Norwich06360	NCT07397338	Map
FL	Florida Cancer Specialists & Research Institute - South	Fort Myers33901	NCT06881784	Map
FL	Mayo Clinic	Jacksonville32224	NCT07252232	Map
FL	Mayo Clinic Cancer Center- Florida	Jacksonville32224	NCT07491445	Map
FL	University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center	Miami33136	NCT07252232	Map
FL	BRCR Global	Plantation33322	NCT06881784	Map
FL	Cancer Care Centers of Breevard	Rockledge32955	NCT06881784	Map
FL	Florida Cancer Specialists	Sarasota34232	NCT06128551	Map
FL	Florida Cancer Specialists	St. Petersburg33701	NCT07252232	Map
FL	Florida Cancer Specialists & Research Institute - North	St. Petersburg33705	NCT06881784	Map
FL	Cleveland Clinic Martin North	Stuart34994	NCT06881784	Map
FL	H Lee Moffitt Cancer Center and Research Institute	Tampa33612	NCT07491445	Map
FL	Moffitt Cancer Center and Research Institute	Tampa33612	NCT06128551	Map
FL	Florida Cancer Specialists & Research Institute - East	West Palm Beach33401	NCT06881784	Map
GA	University Cancer and Blood Center	Athens30607	NCT06881784	Map
GA	Emory University - Winship Cancer Institute	Atlanta30322	NCT07492680	Map
GA	Piedmont Healthcare, Inc	Atlanta30318	NCT06881784	Map
GA	Piedmont Physicians Medical Oncology Atlanta	Atlanta30318	NCT07252232	Map
GA	Winship Cancer Institute	Atlanta30322	NCT06881784	Map
GA	Winship Cancer Institute, Emory University	Atlanta30322	NCT07252232	Map
IL	Center for Care and Discovery	Chicago60637	NCT06881784	Map
IN	Community Health Network	Indianapolis46250	NCT06128551	Map
IN	Community Health Network	Indianapolis46250	NCT07252232	Map
IA	University of Iowa Health Care Cancer Services Quad Cities	Bettendorf52722	NCT06881784	Map
IA	University of Iowa Hospitals & Clinics	Iowa City52242	NCT06881784	Map
IA	University of Iowa Health Care, Mission Cancer + Blood	Waukee50263	NCT06881784	Map
KS	University of Kansas Medical Center Research Institute, Inc.	Lawrence66045	NCT07252232	Map
KS	The University of Kansas Cancer Center	Westwood66205	NCT06881784	Map
MD	Johns Hopkins	Baltimore21231	NCT07349537	Map
MD	Johns Hopkins Hospital	Baltimore21287	NCT07492680	Map
MD	Johns Hopkins Sidney Kimmel Comprehensive Cancer Center	Baltimore21287	NCT07491445	Map
MD	Johns Hopkins University of Medicine	Baltimore21224	NCT06881784	Map
MD	Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins & Sibley Memorial Hospital	Baltimore21287	NCT07252232	Map
MA	Dana Farber Cancer Institute	Boston02215	NCT06128551	Map
MA	Dana Farber Cancer Institute (DFCI)	Boston02215	NCT07252232	Map
MA	Dana-Farber Cancer Institute	Boston02215	NCT07491445	Map
MA	Dana-Farber Cancer Institute	Boston02215	NCT07349537	Map
MA	Massachusetts General Hospital	Boston02114	NCT07252232	Map
MI	Henry Ford Health	Detroit48202	NCT06881784	Map
MI	Karmanos Cancer Institute	Detroit48201	NCT06881784	Map
MI	START Midwest	Grand Rapids49546	NCT06128551	Map
MI	START Midwest	Grand Rapids49546	NCT07349537	Map
MN	Mayo Clinic Cancer Center	Rochester55905	NCT07252232	Map
MN	Mayo Clinic Cancer Center- Rochester	Rochester55905	NCT07491445	Map
MN	Health Partners Cancer Center at Regions Hospital	Saint Paul55101	NCT07397338	Map
MO	Saint Luke's Cancer Institute	Kansas City64111	NCT07252232	Map
MO	Washington University School of Medicine - Siteman Cancer Center	St Louis63110	NCT06881784	Map
MT	St. Vincent Frontier Cancer Center	Billings59102	NCT06881784	Map
NE	University of Nebraska Medical Center	Omaha68198	NCT07252232	Map
NV	Comprehensive Cancer Centers of Nevada	Las Vegas89169	NCT07252232	Map
NH	Dartmouth-Hitchcock Medical Center	Lebanon03756	NCT06881784	Map
NJ	John Theurer Cancer Center at Hackensack UMC	Hackensack07601	NCT06881784	Map
NJ	Morristown Medical Center (MMCORC)	Morristown07960	NCT06881784	Map
NY	Roswell Park Cancer Institute	Buffalo14263	NCT06881784	Map
NY	Columbia University	New York10032	NCT06128551	Map
NY	Columbia University Medical Center	New York10032	NCT07252232	Map
NY	Icahn School of Medicine at Mount Sinai	New York10029	NCT07252232	Map
NY	Laura and Isaac Perlmutter Cancer Center at NYU Langone Health	New York10016	NCT07349537	Map
NY	Laura and Issac Perlmutter Cancer Center at NYU Langone-Ambulatory Care Center	New York10016	NCT07252232	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT07492680	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT06881784	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT07491445	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT06128551	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT07252232	Map
NY	NYU Langone Health	New York10032	NCT06128551	Map
NY	University of Rochester Medical Center	Rochester14642	NCT07252232	Map
NY	Montefiore Medical Center	The Bronx10461	NCT06881784	Map
NC	UNC Lineberger Comprehensive Cancer Center at University of North Carolina	Chapel Hill27599	NCT06881784	Map
NC	Duke Cancer Center	Durham27710	NCT07252232	Map
NC	Duke University Medical Center	Durham27710	NCT07491445	Map
OH	TriHealth Cancer & Blood Institute Research	Cincinnati45220	NCT06881784	Map
OH	University of Cincinnati Cancer Center	Cincinnati45219	NCT07491445	Map
OH	Taylor Cancer Research Center	Maumee43537	NCT06881784	Map
OH	Taylor Cancer Research Center	Maumee43537	NCT07252232	Map
OK	University of Oklahoma	Oklahoma City73104	NCT06128551	Map
OR	Oncology Associates of Oregon PC	Eugene97401	NCT06881784	Map
PA	Penn State Milton S. Hershey Medical Center	Hershey17033	NCT06881784	Map
PA	University of Pennsylvania, Abramson Cancer Center	Philadelphia19104	NCT07252232	Map
PA	Allegheny Health Network	Pittsburgh15212	NCT06128551	Map
PA	UPMC Hillman Cancer Center	Pittsburgh15232	NCT07252232	Map
SD	Avera Saint Luke's Hospital	Aberdeen57401	NCT06881784	Map
SD	Avera Cancer Institute	Sioux Falls57105	NCT06881784	Map
SD	Avera Cancer Institute	Sioux Falls57105	NCT07252232	Map
TN	Sarah Cannon Research Institue	Nashville37203	NCT06128551	Map
TN	SCRI Oncology Partners	Nashville37203	NCT07491445	Map
TN	SCRI Oncology Partners	Nashville37203	NCT07252232	Map
TN	SCRI Oncology Partners - Tennessee	Nashville37203	NCT06881784	Map
TN	Tennessee Oncology	Nashville37023	NCT07397338	Map
TX	Texas Oncology - South Austin	Austin78745	NCT06881784	Map
TX	NEXT - Dallas	Dallas75039	NCT07349537	Map
TX	SCRI - Texas Oncology Dallas	Dallas95246	NCT07491445	Map
TX	Texas Oncology - DFW	Dallas75246	NCT07252232	Map
TX	Texas Oncology Dallas	Dallas75251	NCT06881784	Map
TX	University of Texas, Southwestern Medical Center	Dallas75390	NCT07252232	Map
TX	MD Anderson	Houston77030	NCT06128551	Map
TX	MD Anderson Cancer Center	Houston77030	NCT06881784	Map
TX	MD Anderson Cancer Center	Houston77030	NCT07397338	Map
TX	MD Anderson Cancer Center	Houston77030	NCT07397338	Map
TX	MD Anderson Cancer Center	Houston77030	NCT07491445	Map
TX	NEXT Dallas	Irving75039	NCT07397338	Map
TX	NEXT Dallas	Irving75039	NCT06128551	Map
TX	Texas Oncology - Northeast Texas	Longview75601	NCT07252232	Map
TX	NEXT	San Antonio78229	NCT07349537	Map
TX	NEXT Oncology	San Antonio78229	NCT07397338	Map
TX	NEXT Oncology San Antonio	San Antonio78229	NCT06128551	Map
TX	START - San Antonio	San Antonio78229	NCT07349537	Map
TX	START Texas	San Antonio78229	NCT06128551	Map
TX	Texas Oncology - Gulf Coast	The Woodlands77380	NCT06881784	Map
UT	Huntsman Cancer Institute	Salt Lake City84112	NCT06881784	Map
UT	Huntsman Cancer Institute	Salt Lake City84112	NCT07491445	Map
UT	University of Utah, Huntsman Cancer Institute	Salt Lake City94112	NCT07252232	Map
UT	Utah Cancer Specialists	Salt Lake City84106	NCT06881784	Map
VA	NEXT - Virginia	Fairfax22031	NCT07349537	Map
VA	NEXT Oncology Virginia	Fairfax22031	NCT06128551	Map
VA	NEXT Virginia	Fairfax22031	NCT07397338	Map
VA	Virginia Cancer Specialists	Fairfax22031	NCT06881784	Map
VA	Virginia Cancer Specialists	Fairfax22031	NCT07491445	Map
VA	Virginia Cancer Specialists	Fairfax22031	NCT07252232	Map
WA	Fred Hutchison Cancer Center	Seattle98109	NCT07252232	Map
WA	Virginia Mason Medical Center	Seattle98101	NCT07491445	Map
WI	Froedtert Hospital and the Medical College of Wisconsin	Milwaukee53226	NCT07252232	Map

daraxonrasib clinical trials at a glance: phase × recruitment status

Phase	recruiting	approved for marketing	Total
P1	1		1
P1/P2	2		2
P2	1		1
P3	3		3
N/A		1	1

Recruiting daraxonrasib clinical trials (7)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT ID	Title	Phase	Indication	Enrollment	Started
NCT07492680	A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)	P2	Solid Tumors	260	Jul 2026
NCT06881784	RASolve 301Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)	P3	NSCLC (Non-small Cell Lung Cancer)	590	May 2025
NCT07252232	RASolute 304Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)	P3	Pancreatic Cancer	500	Dec 2025
NCT06128551	Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors	P1/P2	Non-Small Cell Lung Cancer (NSCLC)	534	Nov 2023
NCT07397338	ONStudy of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors	P1/P2	Advanced Solid Tumors	370	Jan 2026
NCT07491445	RASolute 303Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma	P3	Pancreatic Cancer	900	Mar 2026
NCT07349537	Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors	P1	Non-small Cell Lung Cancer (NSCLC)	574	Jan 2026

daraxonrasib clinical trials by indication

Pancreatic Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT07252232	RASolute 304	P3	recruiting	Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07491445	RASolute 303	P3	recruiting	Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Solid Tumors (1)

NCT	Acronym	Phase	Status	Title
NCT07492680	—	P2	recruiting	A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

Advanced Solid Tumors (1)

NCT	Acronym	Phase	Status	Title
NCT07397338	ON	P1/P2	recruiting	Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

Non-small Cell Lung Cancer (NSCLC) (1)

NCT	Acronym	Phase	Status	Title
NCT07349537	—	P1	recruiting	Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

NSCLC (Non-small Cell Lung Cancer) (1)

NCT	Acronym	Phase	Status	Title
NCT06881784	RASolve 301	P3	recruiting	Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Non-Small Cell Lung Cancer (NSCLC) (1)

NCT	Acronym	Phase	Status	Title
NCT06128551	—	P1/P2	recruiting	Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

PDAC (1)

NCT	Acronym	Phase	Status	Title
NCT07573215	RMC-6236	N/A	approved for marketing	Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma

daraxonrasib pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

Acronym	NCT	Phase	Status	Indication	Enrollment	PubMed
RASolve 301	NCT06881784	P3	recruiting	NSCLC (Non-small Cell Lung Cancer)	590	—
RASolute 304	NCT07252232	P3	recruiting	Pancreatic Cancer	500	—
RASolute 303	NCT07491445	P3	recruiting	Pancreatic Cancer	900	—

All daraxonrasib trials (8)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT ID	Acronym	Title	Phase	Status	Enrollment	Sponsor	Started
NCT07492680		A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)	P2	recruiting	260	Bristol-Myers Squibb	Jul 2026
NCT06881784	RASolve 301	Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)	P3	recruiting	590	Revolution Medicines, Inc.	May 2025
NCT07252232	RASolute 304	Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)	P3	recruiting	500	Revolution Medicines, Inc.	Dec 2025
NCT06128551		Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors	P1/P2	recruiting	534	Revolution Medicines, Inc.	Nov 2023
NCT07397338	ON	Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors	P1/P2	recruiting	370	Revolution Medicines, Inc.	Jan 2026
NCT07491445	RASolute 303	Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma	P3	recruiting	900	Revolution Medicines, Inc.	Mar 2026
NCT07349537		Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors	P1	recruiting	574	Revolution Medicines, Inc.	Jan 2026
NCT07573215	RMC-6236	Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma	—	approved for marketing	0	Revolution Medicines, Inc.	—

daraxonrasib clinical trials: frequently asked questions

How many daraxonrasib clinical trials are there?: 8 daraxonrasib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 7 are actively recruiting participants.
Are daraxonrasib clinical trials recruiting in 2026?: Yes — 7 daraxonrasib trials are actively recruiting in 2026, with 144 U.S. sites across 34 states. See the recruiting trials and the per-state site list further down this page.
What conditions is daraxonrasib being studied for?: daraxonrasib is being studied for PDAC, Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma, NSCLC and 21 more. The trials are grouped by indication on this page.
What phase is daraxonrasib in?: daraxonrasib clinical trials span 3 Phase 3, 1 Phase 2, 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors daraxonrasib clinical trials?: The lead sponsor across the most daraxonrasib trials is Revolution Medicines, Inc., with 1 additional lead sponsor listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming daraxonrasibas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed September 24, 2026.

Related pages on Hipa.ai:

daraxonrasib overview daraxonrasib evidence & publications